#China #Shanghai #ZEISS CLARUS 700 #retinal imaging #NMPA approval

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology has officially announced that its innovative CLARUS® 700 device has been granted approval by the National Medical Products Administration (NMPA) in China. This state-of-the-art fundus imaging camera is set to revolutionize retinal diagnostics by offering high-resolution, ultra-widefield images in True Color, enhancing the capabilities of eye care professionals across the country.

Advanced Imaging Technology

The ZEISS CLARUS 700 represents a significant advancement in retinal imaging technology. It integrates ultra-widefield fluorescein angiography (FA) with true-color imaging to deliver unparalleled clarity that allows comprehensive visualization of the retina, from the macular region to the extreme periphery. This capability not only improves diagnostic accuracy but also enhances the workflow within eye clinics, facilitating better patient outcomes and vision preservation.

Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology, highlights the value of this system, stating, "By seamlessly integrating these imaging techniques, the CLARUS 700 facilitates precise decision-making, making it an indispensable tool for ophthalmologists."

Features That Push Limits

The CLARUS 700 boasts impressive specifications, including the ability to capture a full 133° of the retina in a single image and up to 267° with multiple captures. Its advanced features also include:

• - PrecisionFocus: This provides rapid visual access to critical areas of interest, ensuring quicker diagnostic workflows for specialists.
• - QuickCompare: A feature that allows doctors to compare images from previous visitations, aiding in tracking disease progression.
• - AutoBright: This automatic brightness adjustment feature allows ophthalmologists to focus more on analyzing images rather than adjusting settings.

Equipped with these technologically advanced features, the CLARUS 700 is tailored to meet the needs of professionals dealing with retinal diseases, thus enhancing their diagnostic capabilities.

The Impact on Retinal Health in China

The introduction of the CLARUS 700 is particularly timely, given the increasing prevalence of retinal conditions such as diabetic retinopathy in China. With the ability to conduct thorough examinations and assessments of non-perfused retinal areas, the CLARUS 700 is a crucial tool for eye care specialists in delivering timely and accurate diagnoses.

Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China, expressed his enthusiasm for the new device, stating, "The integration of ultra-widefield imaging and AI-enhanced capture will significantly improve diagnostic precision and patient comfort in China."

Looking Ahead

As ZEISS continues to push the frontiers of ophthalmic technology, the approval of the CLARUS 700 marks a pivotal moment in the enhancement of retinal imaging practices. Eye care professionals can look forward to leveraging this tool to unlock the full potential of their clinic's retinal workflow, ultimately leading to improved patient care and vision preservation.

For more information regarding the CLARUS 700 and its capabilities, visit ZEISS Medical Technology today.

The CLARUS 700 not only sets a new standard for fundus imaging but also strengthens ZEISS’s commitment to innovation within the medical device industry. As it becomes adopted in more settings, it promises to be a game-changing asset in the fight against retinal diseases.